Good morning, healthcare professional.
As 2026 Medicare Part D plans take effect, the Inflation Reduction Act's pharmacy provisions are now clear. The new $2,000 annual out-of-pocket cap and Medicare Prescription Payment Plan represent the most significant changes to Part D since 2006. Patient adherence should improve as cost barriers decrease, but pharmacies must navigate new billing processes, education requirements, and cash flow considerations.
In today's healthcare digest:
- Medicare Part D $2,000 cap and payment plan implementation details
- USDA report identifies 1,200 new pharmacy desert communities
- Biosimilar adalimumab products capture 40% of Humira market
- FDA approves first new antibiotic class in over a decade
Medicare Part D $2,000 Cap Takes Effect: What Pharmacies Need to Know
Bottom Line: The $2,000 cap will dramatically reduce cost-related non-adherence among Medicare beneficiaries, particularly for specialty medications. Pharmacies should update systems to process Medicare Prescription Payment Plan installment billing and prepare for increased volume from patients who previously abandoned high-cost prescriptions.
USDA Report Identifies 1,200 New Pharmacy Desert Communities
Bottom Line: The expanding pharmacy desert crisis now affects 41 million Americans, creating public health challenges and strategic opportunities. Telepharmacy regulations enable innovative service models, including mobile pharmacy services and remote dispensing sites for underserved communities.
Biosimilar Adalimumab Products Capture 40% of Humira Market
Bottom Line: Rapid biosimilar market share gains signal an accelerating shift reshaping the specialty landscape. Pharmacies should secure contracts for multiple biosimilar options and prepare to manage therapeutic interchange conversations with patients transitioning from branded Humira.
FDA Approves First New Antibiotic Class in Over a Decade
Bottom Line: The new antibiotic class targeting multi-drug resistant gram-negative infections provides a critical formulary option for hospital and specialty pharmacies. The approval validates the PASTEUR Act incentive model, potentially encouraging further investment in antimicrobial development.
The Shortlist
- Express Scripts announced a pharmacy network tier offering lower copays at pharmacies meeting quality thresholds.
- The DEA proposed new telehealth controlled substance prescribing regulations, extending pandemic-era flexibilities with added safeguards.
- Costco Pharmacy reported 8% prescription volume growth driven by transparent pricing and membership value.
- ASHP published updated guidelines for pharmacist-led anticoagulation management in ambulatory care.
- Generic drug prices fell 3.2% in Q3 2025 per the ADRM Generic Drug Price Index.